-
2023-504716-15-00
6
2021-08-06
Psoriatic Arthritis
-
2023-508738-32-00
4
2021-06-16
Previously untreated and histologically confirmed HER2-Positive
(HER2
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-506498-36-00
5
2021-04-08
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2023-506526-37-00
5
2021-03-17
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2024-513730-38-00
5
2021-01-13
Resectable Non-small cell lung cancer
-
2024-512399-37-00
5
2020-12-29
Generalized Myasthenia Gravis
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-519288-17-00
4
2019-04-26
High-risk Non-muscle Invasive Bladder Cancer
-
2023-505102-42-00
5
2014-12-18
Solid Malignant Tumors
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2024-511057-22-00
5
2024-12-04
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2023-506558-20-00
5
2024-06-26
Dermatitis atopic
-
2023-506084-34-00
5
2024-04-12
Type 2 Diabetes
-
2023-504564-42-00
4
2024-04-08
Moderate to Severe Rheumatoid Arthritis
-
2022-502467-38-00
4
2024-02-22
Non-small cell lung cancer (NSCLC)
-
2023-503957-36-00
10
2023-12-04
Moderate-to-Severe pruritus in adult subjects with notalgia parestheti
-
2023-505144-19-00
6
2023-10-31
Nausea and vomiting of pregnancy
-
2022-501895-25-00
5
2023-09-13
Polymyalgia Rheumatica
-
2023-503565-36-00
4
2023-07-19
ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC)
-
2022-501585-22-00
5
2023-05-11
Atopic Dermatitis